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ABSTRACT Nonsteroidal antiinﬂammatory drugs (NSAIDs), due to their good efﬁcacy in the treatment of pain, inﬂammation,
and fever, are among the most prescribed class of medicines in the world. The main drawback of NSAIDs is that they induce
gastric complications such as peptic ulceration and injury to the intestine. Four NSAIDs, indomethacin, diclofenac, aspirin,
and ibuprofen were selected to induce gastropathy in mouse models. It was found that the addition of C-terminal half of bovine
lactoferrin (C-lobe) reversed the NSAID-induced injuries to the extent of 47–70% whereas the coadministration of C-lobe pre-
vented it signiﬁcantly. The C-lobe was prepared proteolytically using serine proteases. The binding studies of C-lobe with
NSAIDs showed that these compounds bind to C-lobe with afﬁnities ranging from 2.6 to 4.8  104 M. The complexes of
C-lobe were prepared with the above four NSAIDs. All four complexes were crystallized and their detailed three-dimensional
structures were determined using x-ray crystallographic method. The structures showed that all the four NSAID molecules bound
to C-lobe at the newly identiﬁed ligand binding site in C-lobe that is formed involving two a-helices, a10 and a11. The ligand
binding site is separated from the well known iron binding site by the longest and the most stable b-strand, bj, in the structure.
Similar results were also obtained with the full length lactoferrin molecule. This novel, to our knowledge, binding site in C-lobe of
lactoferrin shows a good complementarity for the acidic and lipophilic compounds such as NSAIDs. We believe this indicates that
C-lobe of lactoferrin can be exploited for the prevention of NSAID-induced gastropathy.
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Nonsteroidal antiinflammatory drugs (NSAIDs) are
prescribed extensively all over the world and their current
consumption is among the highest for any drug. The anal-
gesic and antipyretic properties of NSAIDs are very useful
but their long term administration causes a severe damage
in gastroduodenal mucosa resulting in gastric and intestinal
injuries that include peptic ulcer and formation of strictures
in the small and large intestines (1,2). The adverse effects
of NSAIDs to the mucosal cell wall represent a range of
pathologies that may be asymptotic but some are certainly
life threatening (2). It has been indicated that the unbound
NSAID molecules present in the mucosal region of the gut
tend to damage the mucosal lining causing severe ulcers as
a result of prolonged administration (3,4). The existing
methods used for preventing the NSAID-induced gastropa-
thy include co-medication of acid suppressants like proton
pump inhibitors and prostaglandin analogs (5,6). However,
these methods also show side effects and have only limited
efficacy. Hence, to make the applications of NSAIDs safer,
there is an urgent need to develop novel therapeutic agents
that could prevent gastropathy by eliminating the unbound
molecules of NSAIDs. Some reports have shown that bovine
colostrum produces observable effects against NSAID-
induced gastric ulcers (7,8). There are preliminary reports
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to prevent NSAID-induced intestinal injuries in rats and
mice (9,10) indicating that lactoferrin is a main component
of colostrum that is responsible for the useful effects against
NSAID-induced gastropathy. It has been shown recently that
NSAID-like molecules bind to bovine lactoferrin (11,12).
Lactoferrin is an 80-kDa bilobal protein with two similarly
sized N- and C-terminal halves (N- and C-lobes). It has
been shown that lactoferrin can be cleaved by limited prote-
olysis into N- and C-lobes (13). It was further observed that
longer incubations of lactoferrin with proteases results in the
complete digestion of N-lobe whereas C-lobe survives such
an enzymatic degradation (13). We show that the C-lobe of
bovine lactoferrin protects the gastrointestinal tract of mouse
from NSAID-induced gastropathy. The binding studies of
four NSAIDs, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-
H-indole-3-acetic acid (indomethacin), [2-(2,6-dichlorophe-
nylamino) phenyl]acetic acid (diclofenac), 2-(acetyloxy)
benzoic acid (aspirin), and a-methyl-4-(2-methylpropyl)
benzene acetic acid (ibuprofen) carried out with C-lobe
have shown that these NSAIDs bind to C-lobe at affinities
of ~104 M. To identify the site of binding in the C-lobe
and for characterizing the nature of interactions between
C-lobe and NSAIDs, the crystal structures of four complexes
of C-lobe with indomethacin, diclofenac, aspirin and
ibuprofen have been determined. The structure analyses of
these complexes have shown the presence of what we
believe to be a novel ligand binding site in C-lobe that is
located at the back of the well known iron binding cleft in
doi: 10.1016/j.bpj.2009.09.030
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tical region in the new ligand binding site although their
orientations differ slightly. Several residues of the C-lobe
are involved in the interactions with NSAIDs. Such a promis-
cuous mode of binding by C-lobe signifies the importance of
its widely useful sequestering property.
EXPERIMENTAL PROCEDURES
Preparation of C-lobe
Lactoferrin was isolated from bovine colostrum and purified to homogeneity
using the procedure described earlier (15). The freshly purified and lyophi-
lized samples of lactoferrin were dissolved in 50 mM Tris-HCl, pH 8.0 that
are incubated with proteinase K at a lactoferrin/proteinase K molar ratio of
25:1 for 30 min at room temperature. The hydrolyzed product of protein was
passed through a cation exchanger CM-Sephadex (Sigma-Aldrich, St. Louis,
MO) C-50 column (150 mm 15 mm) using a salt gradient of 0.04–0.5 M
NaCl in 0.05 M Tris-HCl, pH 8.0. The fraction corresponding to the 40 kDa
molecular mass was pooled and passed through a gel filtration column (100
mm  10 mm) of Sephadex G-50 in 0.05 M Tris-HCl, pH 8.0. The eluted
protein was dialyzed against deionized water, lyophilized, and stored at
261K. It was confirmed using sodium dodecyl sulfate polyacrylamide gel
electrophoresis and N-terminal sequence determination of the first 20 amino
residues from the N-terminus that the eluted protein was a C-lobe of bovine
lactoferrin (13).
Binding studies
The binding studies of NSAIDs with C-lobe were carried out using
fluorescence spectroscopic technique with spectrofluorometer, FP-6200
(Shimadzu, Koyoto, Japan). C-lobe (2.5 mL at a concentration of 1 
105 mol/L) was loaded in 1-cm quartz cuvette. The concentrations of
NSAIDs were varied by adding increasing volumes of 20 mL, 40 mL,
60 mL, and 80 mL of NSAIDs (indomethacin, aspirin, and ibuprofen) from
their stock solutions of 5  104 mol/L. The fluorescence experiments
were conducted under the conditions of both entrance and exit slit widths
at 5 nm and scanning speed of 240 nm/min. The fluorescence emission
spectra of the protein were recorded in the range of 300–550 nm at an exci-
FIGURE 1 Binding curves, B (indomethacin), 6 (aspirin), and ,
(ibuprofen) showing the change in fluorescence intensities (DF/Fo) at
280 nm as the NSAIDs/C-lobe molar ratio was increased. Indomethacin ex-
hibited slightly large increase in fluorescence as compared to others while
observed. The errors on the experimental points have been indicated.tation wavelength of 280 nm at 298 K (Fig. 1, a–c). The fluorescence spectra
with diclofenac could not be recorded because of its very high intrinsic fluo-
rescence. The spectral changes of the protein were recorded with different
NSAIDs at various concentrations.
Animal studies
The ability of C-lobe to prevent the gastric damage caused by NSAIDs was
established by using mouse animal model. All the mice samples were
procured from the experimental animal house facility of All India Institute
of Medical Sciences, New Delhi. All animal experiments were conducted
in accordance with the guidelines for the care and use of laboratory animals
by CPCSEA (Ministry of Social Justice, government of India) and adopted
by Ethics Committee on Animal Experimentation by the All India Institute
of Medical Sciences. The experiments were carried out on female Swiss
albino mice (age, 6–8 weeks; weight, ~25 g) that were fasted 12 h with
free access to water before the experiment. The doses of C-lobe and NSAIDs
used in these experiments were 200 mg/kg and 10 mg/kg weight of mice,
respectively. All the preparations were made in phosphate buffer saline
(PBS) containing 50 mM potassium phosphate; 150 mM NaCl; pH 7.2.
The animals were randomized in three groups designated as control, NSAID,
and the test group with C-lobe þ NSAID. At zero time animals of the test
and NSAID groups were treated orally with NSAIDs (10 mg/kg weight of
mice) whereas PBS was given to the animals of control group. After 1 h,
200 mg/kg of C-lobe was administered orally to the test group and PBS
was given to the control and NSAID groups; 24 h later, all animals were
euthanized and the whole gut was removed for the analysis of bleeding
and inflammation index. The analysis of intragastric bleeding was carried
out by measuring the concentration of hemoglobin. The distal end of the
small intestine was excised and flushed with 2 mL of distilled water for
the hemoglobin assay. In addition, ileal tissues from small intestine were
excised and processed for myeloperoxidase (MPO) assay that is known to
act as an index of inflammation (16).
Hemoglobin assay
The hemoglobin concentration that is an indicator of intragastric bleeding
was estimated using the modified method of Crosby and Furth (17);
~25 mL of the test sample was added to 1 mL reaction mixture containing
1% benzidine/HCl in acetic acid þ 1% H2O2 and incubated it for 20 min.
This was followed by the addition of 5 mL diluent consisting of 10% acetic
acid incubated for 10 min. The absorbance was measured spectrophotomet-
rically using a spectrophotometer Cary 100 Bio (Varian, Palo Alto, CA) at
a wavelength of 515 nm.
Myeloperoxidase assay
The indicator of tissue neutrophil accumulation of MPO activity was deter-
mined using the modified method of Brandley et al. (16). The equally
weighed ileal tissues of three experimental groups were homogenized in
50 mM phosphate buffer, pH 6.0 containing 0.5% hexadecyltrimethylam-
monium bromide. It was sonicated and freeze-thawed, and followed by
centrifugation for 40 min at 12000 rpm. An aliquot (0.1 mL) of the superna-
tant was allowed to react with 2.9 mL of buffer containing O-dianisidine
(0.167 mg/mL) and 0.0005% H2O2. The rate of change in absorbance was
measured spectrophotometrically, using a spectrophotometer Cary 100 Bio
(Varian), at 460 nm. The results were expressed as units of MPO per mg
of protein. The protein was estimated using bicinchoninic acid method using
bovine albumin as a standard.
Statistical analysis
All values are statistically derived and presented as mean 5 SE. The
comparison among the groups was made using one-way analysis of vari-
ance. The differences with p-values < 0.05 were considered significant.Biophysical Journal 97(12) 3178–3186
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The C-lobe was cocrystallized with four NSAIDs (indomethacin, diclofenac,
aspirin, ibuprofen) using identical molar ratios (1:20) of protein to NSAIDs.
A protein solution (80 mg/mL) was prepared in the buffer containing 20%
ethanol and 50 mM MES at pH 6.5. The samples of NSAIDs were added
to this solution and allowed to stay for 24 h at 298 K. The incubated protein
solutions were mixed in a 1:1 ratio with crystallization buffer containing
0.1 M MES pH 6.5, 25% (v/v) polyethylene glycol monomethyl ether
550, and 0.01 M zinc sulfate heptahydrate, and allowed to equilibrate via
vapor diffusion over 1-mL well solution consisting of above crystallization
buffer at 298 K. The irregular-shaped and dark brown-colored crystals of the
complexes appeared after two days.
Detection of indomethacin, diclofenac, aspirin,
and ibuprofen in crystals
To confirm the presence of indomethacin, diclofenac, aspirin, and ibuprofen
in the crystals of C-lobe complexes, the crystals of four complexes were used
for the identifications of indomethacin, diclofenac, aspirin, and ibuprofen.
Initially, the crystals were washed with distilled water and dissolved in the
buffer containing 50 mM Tris-HCl, pH 8.0 separately. These crystal solu-
tions were ultrafiltered in the same buffer containing 1 M NaCl using a
membrane with a cutoff of 1 kDa.
The presence of indomethacin in the filtrate was observed by adding
ammonium oxalate and concentrated sulphuric acid followed by heating
the contents in the water bath. Indomethacin reacts with oxalate ions in
acidic solution to form a violet-colored complex and the absorbance of
this complex was measured at wavelength of 578 nm using the spectropho-
tometer Lamda 25 (PerkinElmer, Boston, MA).
The presence of diclofenac in the filtrate was observed by adding Fe3þ
ions and 2,20-bipyridine. Diclofenac reduces Fe3þ to Fe2þ on heating in
aqueous solution and the ferrous ions produced reacts with 2,20-bipyridine
to form a complex and its absorbance was measured at wavelength of
520 nm using the spectrophotometer Lamda 25 (PerkinElmer).
The presence of aspirin in the filtrate was observed by adding Fe3þ ions.
When treated with basic solution the acetylsalicylic acid hydrolyzes quickly
to salicylic acid. The salicylate ions form an intensely purple-colored
complex with the ferric ion in acidic solution and the absorption of this
complex was measured at wavelength of 530 nm using the spectrophotom-
eter Lamda 25 (PerkinElmer).
X-ray intensity data collection and processing
The freshly grown crystals of all four complexes of C-lobe with NSAIDs
were used for x-ray crystallographic studies. The intensity data were
collected at 287 K using a 345 mm diameter MAR Research Imaging plate
scanner (Marresearch, Norderstedt, Germany) mounted on a RU-300 Rigaku
rotating anode x-ray generator (Rigaku, Tokyo, Japan) operating at 50 kV
and 100 mA. The Osmic Blue confocal optics (Rigaku) was used for
focusing Cu Ka radiation. The data were processed with DENZO and
SCALEPACK from HKL package (18). The crystals of four complexes
are isomorphous and belong to monoclinic space group P21. The summary
of data collection statistics for all the four complexes is given in Table 1.
Structure determination and reﬁnement
The structures of all four complexes were determined with molecular
replacement method using AMoRe (19). The coordinates of native C-lobe
(14) (Protein Data Bank code: 1NKX) were used as the search model.
The rotation and translation search functions were calculated with data
between the resolution range of 12.0–4.0 A˚ yielding clear solutions with
distinct peaks for the four structures. The transformed coordinates using
AMoRe (19) were initially subjected to 40 cycles of rigid body refinements.
Density modifications and crystallographic refinement procedures wereBiophysical Journal 97(12) 3178–3186carried out using ARP/wARP (20) and REFMAC (21) respectively. The
model buildings were carried out using program O (22). The difference
Fourier jFo  Fcj at 3s and Fourier j2Fo  Fcj maps at 1s before inclusion
of ligands were calculated at Rcryst factors of%0.24 in all the cases. These
showed reasonably characteristic electron densities at the ligand binding site
in the C-lobe. The ligands were modeled into the respective electron densi-
ties (Fig. 2, a–d) and their coordinates were included in the subsequent
cycles of refinements. Note that the fitting of aspirin in the electron density
is slightly ambiguous as it can be adjusted in two orientations in which either
carboxylic group or acetyl group could be placed in the proximity of the side
chain of Thr663. However, chemical considerations such as the possibility
of hydrogen bond formation favor the present mode of binding. The position
of metal ions, Fe3þ and Zn2þ, anions CO3
2, and SO4
2, atoms of sugar
residues from three glycan chains and water oxygen atoms were also deter-
mined. All these atoms were included in the subsequent refinement cycles.
The refinements converged with Rcryst/Rfree factors of 0.209/0.244, 0.193/
0.219, 0.182/0.228, and 0.165/0.220 for the complexes with indomethacin,
diclofenac, aspirin, and ibuprofen, respectively. The refinement statistics of
these structures are summarized in Table 1.
RESULTS
Analysis of binding studies
To exploit the fluorescence properties of proteinmolecule, the
binding studies were carried out as described in Experimental
Procedures. The intrinsic fluorescence ofC-lobewhen excited
at 280 nm is due to the presence of at least four aromatic resi-
dues, which are located in the proximity of the binding pocket.
The fluorescence spectra were recorded in the presence of
increasing amounts of NSAIDs. The fluorescence intensities
of C-lobe decreased gradually when the concentrations of
NSAIDs were enhanced although the positions of emission
maxima as well as the shape of the peaks remained unaltered.
This suggested that NSAIDs bound to C-lobe without altering
the environment in the vicinity of aromatic residues. The
observed fluorescence data were used for calculating the fluo-
rescence quenching (Q ¼ (Fo  F)/Fo, where F is the
measured fluorescence and Fo is the fluorescence in
the absence of NSAIDs). Plots of graph of Q (%) against
the molar ratios of ligand/protein were prepared. As seen
from Fig. 1, it gave rise to three smoothly rising curves for
the binding of indomethacin, aspirin, and ibuprofen. The
least-squares fit of the fluorescence intensity changes for the
NSAID-C-lobe binding curves were obtained by Sigma Plot
8.0 (23). TheR2 values for the fit curves of the binding of indo-
methacin, aspirin, and ibuprofen to C-lobe are 0.98, 0.96, and
0.99, respectively. The error bars on the experimental points
were estimated from the average of values that were obtained
by repeating each experiment six times. The binding constants
were calculated using the binding equation described by
Scatchard (11,12). From these curves binding constants for
indomethacin, aspirin, and ibuprofen were obtained. The
approximate values of binding constants were found to be
2.6 104M, 3.3 104M, and 4.8 104M for indometh-
acin, aspirin, and ibuprofen, respectively indicating that all
the compounds were attached to C-lobe at an approximate
affinity of 104 M.
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Parameters (a) C-lobe indomethacin (b) C-lobe diclofenac (c) C-lobe aspirin (d) C-lobe ibuprofen
Data collection
Space group P21 P21 P21 P21
Unit cell dimensions (A˚)
a 63.8 61.4 63.3 63.3
b 50.6 49.9 50.5 50.5
c 66.1 66.1 65.9 66.1
b () 107.6 107.1 107.7 107.7
Molecules in the unit cell (n) 2 2 2 2
Vm (A˚3/Da) 2.5 2.4 2.5 2.7
Solvent content ~51.0 ~48.0 ~51.0 ~54.3
Resolution range (A˚) 20.0–2.2 (2.25–2.20) 20.0–1.4 (1.43–1.40) 20.0–2.0 (2.07–2.00) 20.0–2.3 (2.35–2.30)
Total measured reflections (n) 113,121 613,858 153,732 156,288
Unique reflections (n) 20,430 74,524 27,067 15,841
Redundancy 6.5 5.6 7.4 6.4
Overall completeness of data 91 (93) 99.7 (98.5) 96.1 (90.2) 90.0 (90.2)
Overall Rsym 12.4 (48.0) 6.2 (45.0) 7.1 (40.3) 12.5 (47.7)
Overall I/s(I) 9.8 (2.2) 17.5 (2.0) 13.2 (2.5) 6.4 (2.0)
Refined model
Protein Data Bank code 3IB1 3IB0 3IAZ 3IB2
Rcryst (%) 20.9 19.3 18.2 16.5
Rfree (%) 24.4 21.9 22.8 22.0
Protein atoms 2605 2605 2605 2605
Fe3þ ion 1 1 1 1
Zn2
þ ions 2 2 2 2
CO3
2 ion 1 1 1 1
SO4
2 ion 1 1 1 1
Sugar residues (N-linked) 11 13 13 7
Atoms of ligand 25 19 13 15
Water molecules 247 509 260 143
RMSD* in bond length 0.02 0.01 0.01 0.01
RMSD in bond angles 2.2 1.7 1.7 1.7
RMSD in torsion angles 20.4 16.9 17.9 18.3
Overall G factor 0.04 0.04 0.07 0.1
Mean B-factor (A˚2)
Main chain atoms 34.6 17.7 27.9 29.4
Side chain atoms 36.8 20.2 30.7 31.7
Water molecules 52.2 38.9 46.3 41.7
All atoms 39.0 23.5 33.7 32.5
Ramachandran plot residues (%)
Residues in the most favored regions 85.4 88.0 89.0 83.7
Residues in the additionally allowed regions 14.3 11.7 10.6 15.0
Residues in the generously allowed regions 0.0 0.0 0.0 1.0
Residue in the disallowed regions (Leu640) 0.3 0.3 0.3 0.3
Values in parentheses are for the highest resolution shell.
*RMSD, root mean-square deviation.Analysis of studies in vivo
Gastric bleeding
The examination of gastric hemoglobin concentration gives
an index of gastric bleeding. The administration of NSAIDs
in mice increased the hemoglobin concentration due to
induced gastric injury (p < 0.05; Fig. 3 i, A). The orally
administered C-lobe in mice after the administration of
NSAIDs showed reduction in hemoglobin concentration
considerably (p < 0.05; Fig. 3 i, B). When compared with
the concentration of hemoglobin in NSAIDs treated mice,
it corresponded to a recovery to the extent of 60% in indo-methacin-induced injury, 52% in diclofenac-induced injury,
51% in aspirin-induced injury, and 47% in ibuprofen-
induced injury. The values after recovery in the cases of
indomethacin and diclofenac were slightly higher than those
of control samples (p< 0.05; Fig. 3 i, C) whereas in the cases
of aspirin and ibuprofen, the hemoglobin concentrations
after the administration of C-lobe were comparable to those
observed in the control samples (p < 0.05; Fig. 3 i, C). This
indicates that the effect of C-lobe was significant in reducing
the gastric bleeding in mice treated with NSAIDs. In a sepa-
rate experiment when C-lobe was coadministered with
NSAIDs, it prevented any injuries completely.Biophysical Journal 97(12) 3178–3186
3182 Mir et al.FIGURE 2 Initial jFo  Fcj difference Fourier maps
calculated at Rcryst ¼ 0.24 before inclusion of ligands
showing electron densities at 3s cutoff (along side in the
box j2Fo  Fcj maps at 1s cutoff) for the ligands (a) indo-
methacin, (b) diclofenac, (c) aspirin, and (d) ibuprofen.MPO activity
The infiltration of neutrophils during gastric injury, as an
index of inflammation, was measured by the activity of
marker enzyme MPO. The enhancement in neutrophil
migration was observed as an increase in the MPO activity
(p < 0.05; Fig. 3 ii, A) in ileum tissue after NSAIDs were
administered to the mice that were significantly higher as
compared to control (p < 0.05; Fig. 3 ii, C). When the
C-lobe was orally administered to mice after giving the
dosage of NSAIDs, it reduced the activity of MPO consid-
erably and the recoveries occurred to the extent of 70%,
69%, 60%, and 68% from the injuries induced by indometh-
acin, diclofenac, aspirin, and ibuprofen, respectively (p <
0.05; Fig. 3 ii, B) as compared to only NSAIDs treated
mice. These values were comparable to the values obtained
for control samples (p < 0.05, Fig. 3 ii, C). The lowering
of MPO activity of samples clearly indicates the repairing
role played by the C-lobe. As in the case of gastric bleeding,
when C-lobe was coadministered with NSAIDs, the
MPO activity in the ileum tissue was found to be signifi-
cantly low.Biophysical Journal 97(12) 3178–3186Structural analysis
The final models of the complexes of C-lobe with indometh-
acin, diclofenac, aspirin, and ibuprofen have been summa-
rized in Table 1 (a–d, respectively). The structure of the
proteolytically prepared C-lobe of bovine lactoferrin consists
of residues from 342 to 676. The structural organization of
C-lobe is comprised of 12 a-helices, and 11 b-strands. The
structure of C-lobe is divided into two similarly sized
domains, C-1 and C-2. The C-1 domain is comprised of
six a-helices and six b-strands, whereas the domain C-2 is
made up of six a-helices and five b-strands. The deep iron
binding cleft is formed between domains C-1 and C-2. The
base of the iron binding cleft is closed by the longest b-strand
in the structure. The structures of four complexes of C-lobe
with indomethacin (Fig. 4 a), diclofenac (Fig. 4 b), aspirin
(Fig. 4 c), and ibuprofen (Fig. 4 d) show a common binding
site for all the four NSAID molecules. All the four ligands
are located at the site in the back of the iron binding
site. This site is structured into a shallow cleft. It is formed
with an a-helix, a10, a b-strand, bj, and including two
loops, one between helices a10 and a11 and the otherFIGURE 3 Effect of C-lobe on acute NSAID-induced
intestinal injury in mice. The mice were treated as
described in the methods. (i) Rinses of the distal small
intestinal lumen were analyzed for hemoglobin: (A)
samples treated with (a) indomethacin, (b) diclofenac, (c)
aspirin, and (d) ibuprofen; (B) C-lobe was administered
orally to the mice after the treated with (a) indomethacin,
(b) diclofenac, (c) aspirin, and (d) ibuprofen; and (C)
control samples treated with PBS. The results are presented
as mean5 SE, n¼ 15, p< 0.05. (ii) The ileal tissues were
analyzed for MPO activity: (A) samples treated with (a)
indomethacin, (b) diclofenac, (c) aspirin, and (d) ibuprofen;
(B) on adding C-lobe after the NSAIDs were added (a)
indomethacin, (b) diclofenac, (c) aspirin, and (d) ibuprofen;
and (C) in control samples. Results are presented as mean
5 SE, n ¼ 15, p < 0.05.
Prevention of NSAID-Induced Gastropathy 3183FIGURE 4 Binding of NSAIDs in the ligand-binding
site of C-lobe. Protein residues are shown in green and
NSAID molecules are yellow: (a) indomethacin, (b) diclo-
fenac, (c) aspirin and (d) ibuprofen. Dashed lines indicate
hydrogen bonds. Residues are labeled.between b-strands bd and be. This binding site has an
opening to the surface of the protein. The NSAID binding
site consists of hydrogen bond forming features involving
Thr663 and the backbone N atoms on one side and hydro-
phobic residues Pro429, Thr430, Val591, Pro593, Leu651, and
Pro655 on the opposite side. It has dimensions of the order
of 16 A˚ in length and 8 A˚ deep from the surface and seems
to be specific to acidic and lipophilic ligands such as NSAID
molecules.
Binding of NSAIDs to C-lobe
Structure of the complex of C-lobe with indomethacin
The structure of the complex of C-lobe with indomethacin
has been determined at 2.2 A˚ resolution. The crystals were
obtained by cocrystallization using protein to indomethacin
molar ratio of 1:10. The unit cell dimensions were found
to be a ¼ 63.8 A˚, b ¼ 50.6 A˚, c ¼ 66.1 A˚, and b ¼
107.6. As illustrated in Fig. 4 a, indomethacin is held
parallel to the surface in the NSAID binding site with its
carboxylic group forming several hydrogen bonds with
Thr663 and a water molecule. The hydrophobic interactions
are provided by Gly662, Thr430, and Pro429. Indomethacin
is bound firmly at two ends. On one side it forms hydrogen
bonds whereas the second side is held by van der Waals
forces indicating a typical model for the compounds having
both hydrophilic and hydrophobic moieties as in NSAIDs.
Indomethacin covers ~26% volume of the ligand binding
site (Fig. 5 a).Structure of C-lobe complex with diclofenac
The structure of the complex formed between C-lobe and
diclofenac was determined at 1.4 A˚ resolution. The crystals
of the complex formed between C-lobe and diclofenac
were obtained by cocrystallizing the C-lobe with diclofenac
at 1:10 molar ratio. The unit cell dimensions were deter-
mined to be a ¼ 61.4 A˚, b ¼ 49.9 A˚, c ¼ 66.1 A˚, and b ¼
107.1. As seen from Fig. 4 b, Thr663 forms three direct
hydrogen bonds and one through solvent water molecule
with the carboxylic group of diclofenac. The residues
Gly662, Pro593, and Val591 provide van der Waals contacts
at the other end. The diclofenac molecule is fitted into the
newly identified ligand binding site of C-lobe and occupies
~21% volume of the ligand binding site (Fig. 5 b).
Structure of C-lobe complex with aspirin
The structure of the complex formed between C-lobe and
aspirin was determined at pH 6.5 as similar conditions
were used for the spectroscopic studies of this complex.
The crystals of the complex were obtained by cocrystalliza-
tion using the mixture of C-lobe with aspirin at 1:10 molar
ratio. The cell dimensions were a ¼ 63.3 A˚, b ¼ 50.5 A˚,
c ¼ 65.9 A˚, and b ¼ 107.7. As seen from Fig. 4 c, aspirin
binds to C-lobe at the NSAID binding site and forms two
direct hydrogen bonds involving one of the carboxyl group
oxygen atoms of aspirin with Thr663 NH (Thr663 NHO1
aspirin ¼ 2.9 A˚) and OgH (Thr663 OgHO1 aspirin ¼
2.8 A˚). There are three other hydrogen bonds involving
Glu659 O Tyr660 O with O3 of aspirin through solvent waterBiophysical Journal 97(12) 3178–3186
3184 Mir et al.FIGURE 5 Placement of NSAID molecules in the
ligand-binding site. The molecules of (a) indomethacin,
(b) diclofenac, (c) aspirin, and (d) ibuprofen are shown
well fitted in the figure (drawn using grasp) (26).molecule W118 (aspirin O3W118 ¼ 3.3 A˚, W118O
Glu659 ¼ 3.1 A˚, and W118O Tyr660 ¼ 3.0 A˚). Another
acetyl group oxygen atom O4 forms a hydrogen bond with
ethanol OH at a distance of 2.7 A˚. The methyl group of
ethanol, on the other hand, forms strong van der Waals
contacts with Pro655, Glu659, and Gly662. The position of
aspirin molecule indicates that it occupies a 14% volume of
the ligand binding site in the proximity of Thr663 (Fig. 5 c).
Structure of the complex of C-lobe with ibuprofen
The crystals of the complex of C-lobe with ibuprofen were
obtained using cocrystallization by mixing C-lobe and
ibuprofen at 1:10 molar ratio. The cell dimensions were
found to be a ¼ 63.3 A˚, b ¼ 50.5 A˚, c ¼ 66.1 A˚, and b ¼
107.7. Ibuprofen binds to C-lobe at the same site that is
occupied by indomethacin, diclofenac, and aspirin. The
interactions between C-lobe and ibuprofen involve two
hydrogen bonds and three notable van der Waals contacts
(Fig. 4 d). As seen in Fig. 5 d, it is fitted into the cleft
covering ~17% volume of the ligand binding site.
The structures of the complexes of C-lobe with four
NSAIDs indicate that a new independent ligand binding
site is present in the C-lobe of lactoferrin. This site is partic-
ularly suitable for the binding of NSAIDs and it is highly
accessible from the surface. This is also independent from
the other role of C-lobe of carrying out the iron binding
and release. Therefore this can act as a sequesterer in both
iron saturated and apo form of C-lobe. This NSAID binding
property of C-lobe seems to be responsible for its effects
against gastric ulcers.Biophysical Journal 97(12) 3178–3186DISCUSSION
The effect of sequestration of NSAIDs by C-lobe does not
hamper the efficiency of their binding to the target proteins
because the binding affinities of NSAIDs to PLA2 and
COX-2 enzymes are significantly higher (106 to 108 M)
than their affinities toward C-lobe (z104 M). On the other
hand, the human serum albumin (HSA) also has been shown
to sequester NSAIDs through more than one binding site with
affinities of the order of 106 to 107M (24,25). These affin-
ities are comparable to those of NSAIDs with PLA2 and
COX-2 target proteins. As a result, HSA is unsuitable for
coadministration for sequestering the unbound NSAIDs as it
impairs the availability of drug molecules due to their high
affinities for HSA (25). We believe the experiments carried
out to study the side effects of NSAIDs on mouse models
using indomethacin, diclofenac, aspirin, and ibuprofen show
clearly that the significant damages occur to the gastric
mucosal lining. The observed concentrations of gastric hemo-
globin after the administration ofNSAIDs show that the levels
of hemoglobin increase considerably. The concentrations of
the marker proteins indicate that the lesions caused by
NSAIDs on gastric mucosal lining are maximum with
indomethacin whereas diclofenac produces 80% of the
damage produced by indomethacin whereas both aspirin and
ibuprofen cause significantly lower damages than that caused
by indomethacin (Fig. 3 i, A). However, when C-lobe was
administered, the levels of hemoglobin dropped considerably
(Fig. 3 i, B). Similar results were obtained when the activity of
lower intestinal myeloperoxidase (MPO) was estimated
(Fig. 3 ii, A). As seen from Fig. 3 ii, A, the activity of MPO
Prevention of NSAID-Induced Gastropathy 3185increased nearly 3–5 times when NSAIDs were administered.
Again the maximum damage was caused by indomethacin.
When C-lobe was administered, the recorded activity of
MPO dropped nearly to the levels of values obtained for the
controlled cases indicating a complete reversal of NSAID-
induced gastropathy. In other experiments with mouse
models, when C-lobe was coadministered with NSAIDs, the
gastric lesions were not observed. The binding studies for
NSAIDs with C-lobe show that indomethacin, diclofenac,
aspirin, and ibuprofen bind to C-lobe with affinities ranging
from 2.6 to 4.8  104 M that seem to be good enough to
sequester the unbound molecules in the gut without affecting
the efficacy of the drugs. The structural studies have shown
the presence of a single promiscuous binding site that is suit-
able for compounds with acidic and lipophilic nature such as
those of NSAIDs. This is a shallow cleft on the surface of the
protein that is situated at the back of the well formed deep
hydrophilic iron-binding cleft in the C-lobe. It is well sepa-
rated from the iron binding site by the longestb-strandbj (resi-
dues, 590–602) in the structure of C-lobe. The new ligand
binding site is comprised of protein segments, 429–432
(loop, bd–be), a part of b-strand bj (residues, 570–593), apart
of a-helix, a10 (residues, 658–666), and a loop between
a-helices a10 and a11 (residues 661–664). On one side, the
site is rich in hydrophobic environment whereas at the oppo-
site end, it has favorable hydrogen bond formers. As a result,
this binding site in C-lobe attracts the ligands with lipophilic
and acidic characters. The site is nearly 16 A˚ long and ~8 A˚
deep. The sizes of NSAID molecules are within the range of
12 A˚ in length and 6 A˚ width. Thus the dimensions of the
binding site in C-lobe can accommodate various NSAIDs.
In comparison, the HSA has two large binding cavities with
dimensions of 16 A˚  15 A˚. The drug binding site in HSA
consists of apolar residues and basic residues with a complete
absence of acidic residues providing a clear definition of spec-
ificity of the binding. This supports the observed high affinity
of z107M for NSAIDs (25). All compounds studied are
reported to be positioned overlappingly to make contacts
either through hydrogen bonds or salt bridges in addition to
extensive hydrophobic interactions. In the case of C-lobe,
all four molecules occupy same regions of the binding site
although their orientations differ slightly (Fig. 5). On binding
of NSAIDs, the residues of the ligand binding site, Asn414,
Thr430, Glu431, Pro655, Tyr660, Thr663, and Glu664 undergo
minor conformational adjustments. The root mean-square
shifts for the side chains of above residues in the complexes
of C-lobe with indomethacin, diclofenac, aspirin, and
ibuprofen when superimposed on the same residues of the
native structure (14) were found to be 0.7 A˚, 1.0 A˚, 0.9 A˚,
and 0.8 A˚, respectively.
CONCLUSION
These structural and binding studies of C-lobe complexes
with NSAIDs show that NSAIDs bind to C-lobe at a commonsite indicating the presence of a new ligand binding site in
C-lobe of lactoferrin. The binding affinities of C-lobe for
indomethacin, diclofenac, aspirin, and ibuprofen are of the
order of 104 M. Therefore, C-lobe is capable of seques-
tering the unbound NSAIDs in the gut resulting in the
reversal of NSAID-induced gastropathy. Because C-lobe is
resistant to enzymatic degradation, its sequestering property
has potentially useful therapeutic applications. The bindings
of NSAIDs to C-lobe unlike to that of human serum albumin
does not hamper the availability of drugs because the binding
constant of NSAIDs with C-lobe is considerably lower than
that reported for NSAIDs with targets, COX-2, and PLA2. In
this respect, human serum albumin is unsuitable because it
has a high binding constant for NSAIDs (107 M) that is
comparable to that of actual drug targets (106–108 M).
Therefore, coadministration of C-lobe with NSAIDs offers
a great advantage for the prevention of NSAID-induced gas-
tropathy. We believe the animal studies support these
conclusions unambiguously.
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